# Yashoda Hospitals Puts IPO on Hold and Explores 8-10% Promoter Stake Sale at Up to $3.2 Billion

> Yashoda Hospitals has shelved its IPO and is in advanced talks to sell an 8-10% promoter stake, targeting a valuation of up to Rs 30,000 crore ($3.2 billion).

- Published: 2026-11-22T17:47:46+00:00
- Section: IPOs & Listings
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-22/yashoda-hospitals-ipo-stake-sale
- Source: [Business News Today](https://www.moneycontrol.com/news/business/companies/yashoda-hospitals-defers-ipo-explores-part-stake-sale-targeting-up-to-3-2-bn-valuation-14086691.html)

## Key takeaways

- Yashoda Hospitals deferred its IPO and is exploring a part stake sale at a valuation of up to Rs 30,000 crore ($3.2 billion).
- The secondary sale could dilute the promoter stake by around 8% to 10% and may include primary funds for inorganic growth.
- Yashoda reported revenue from operations of Rs 3,399.07 crore and net profit of Rs 766.22 crore in fiscal 2025.

Yashoda Hospitals has deferred its proposed initial public offer and is exploring a part stake sale in the company at a valuation of up to Rs 30,000 crore ($3.2 billion), [Business News Today](https://www.moneycontrol.com/news/business/companies/yashoda-hospitals-defers-ipo-explores-part-stake-sale-targeting-up-to-3-2-bn-valuation-14086691.html) reported, citing four people familiar with the matter who spoke on condition of anonymity.

## Yashoda's Stake Sale Plan and IPO Hold

Yashoda Healthcare Services, which operates as [Yashoda Hospitals](https://akta.pro/company-profiles/0009u93/yashoda-hospitals), filed a draft red herring prospectus through the confidential pre-filing route in September 2025 and received the market regulator's nod in December. One of the people said the IPO is on hold and will be explored at a later stage depending on market conditions and firm strategy, adding that a promoter family member is keen to unlock value and monetize a minority stake.

A second person said the secondary sale could dilute around 8% to 10% of the stake and that the company is looking at major greenfield hospital expansion in Bengaluru. If the transaction goes through, it will set a valuation benchmark ahead of a future listing, according to the report.

"Yashoda Hospital is a good, large, profitable business. If required, the deal may also see some funds raised through the primary route, for inorganic growth," a third person said. A fourth person confirmed the listing plans had been postponed and work on the public issue had ceased, and said the company is in advanced discussions to appoint advisors, with private equity firms potentially expressing interest in the stake sale process.

An email query to Yashoda Hospitals was left unanswered at the time of publishing, the report said. The chain was founded by three brothers, Ravender Rao, G Devender Rao and Dr G Surender Rao, and its revenue from operations reached Rs 3,399.07 crore in fiscal 2025 alongside a net profit of Rs 766.22 crore, according to IPO Index.

## Yashoda's Hospital Network and Recent Moves

According to akta.pro [company records](https://akta.pro/company-data), Yashoda Hospitals operates 2,756 beds across four hospitals, four heart institutes and four cancer institutes, with more than 646 specialist doctors. The records list a February 2026 partnership with Qure.ai to deploy AI-powered lung cancer detection in radiology and oncology workflows, and a February 2026 AI-enabled E-ICU command centre at Yashoda Medicity in Ghaziabad connected to MMG District Hospital.

## Earlier Expansion at Yashoda Medicity

In September 2026, Yashoda Group of Hospitals said it planned to add 600 beds to its 625-bed Yashoda Medicity facility and was targeting operational break-even within three years, Business Today reported. That month, Yashoda Medicity also signed a three-year memorandum of understanding with Turkistan City in Kazakhstan covering patient referrals, training and knowledge exchange, according to Digital Health News. In August 2026, Yashoda Hospitals appointed Hitesh Dhaddha as group chief financial officer with a remit covering corporate strategy, growth initiatives, M&A, capital markets and strategic finance, Medical Buyer reported.

## Companies in this story

- [Yashoda Hospitals company profile](https://akta.pro/company-profiles/0009u93/yashoda-hospitals) · website: https://www.yashodahospitals.com

---
News for Agent · https://newsforagent.com/llms.txt
